# Imsidolimab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/imsidolimab

> The PDUFA target action date for imsidolimab, sponsored by Vanda Pharmaceuticals Inc. (VNDA), is December 12, 2026. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the imsidolimab PDUFA date?

The PDUFA target action date for imsidolimab, sponsored by Vanda Pharmaceuticals Inc. (VNDA), is December 12, 2026. Status: scheduled. Press release filed with the SEC (EX-99): "•QuimilzaTM (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026" Last confirmed November 12, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/imsidolimab)

Source: Press release filed with the SEC (EX-99), accession 0001628280-26-053308, https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/pdufa/imsidolimab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | imsidolimab |
| Codes |  |
| Sponsor | Vanda Pharmaceuticals Inc. (VNDA) https://sec-api.dev/companies/vnda/catalysts |
| Indications |  |
| Modality | antibody |
| FDA designations | priority review |

## Timeline

### Dec 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-02-12, last confirmed 2026-02-12.
- SEC Form 10-K (accession 0001628280-26-007460): "In December 2025, we submitted the Biologics License Application (BLA) for imsidolimab for the treatment of GPP and requested priority review of the BLA." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm

### Feb 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-03-03, last confirmed 2026-03-03.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-088239): "FDA accepted the BLA filing for imsidolimab in generalized pustular psoriasis (GPP) in Feb. 2026 with a target action date of Dec. 12, 2026" https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-ex99_1.htm

### February 21, 2026: NDA/BLA submission

- Status: scheduled. Date confidence: exact.
- First seen 2025-10-29, last confirmed 2025-10-29.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-047112): ""We are particularly encouraged by our advancing pipeline, with multiple near-term regulatory milestones: the tradipitant NDA for motion sickness under FDA review with a PDUFA target action date of December 30, 2025; the Bysanti NDA for bipolar I disorder and schizophrenia also under FDA review with a PDUFA target action date of February 21, 2026; and the anticipated Q4 submission of the imsidolimab BLA for generalized pustular psoriasis." https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda8-k10292025exhibit991.htm

### December 12, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-03-03, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-053308): "•QuimilzaTM (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026" https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-031241): "•Imsidolimab BLA for Generalized Pustular Psoriasis accepted for FDA review; PDUFA target action date of December 12, 2026" https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/vnda8-k562026exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-031241): "•The FDA accepted the Biologics License Application (BLA) for imsidolimab in Generalized Pustular Psoriasis (GPP) with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026." https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/vnda8-k562026exhibit991.htm
- SEC Form 10-Q (accession 0001628280-26-031667): "•The FDA accepted the Biologics License Application (BLA) for imsidolimab in Generalized Pustular Psoriasis (GPP) with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026." https://www.sec.gov/Archives/edgar/data/1347178/000162828026031667/vnda-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219500): "FDA target action date (PDUFA) of Dec. 12, 2026 for imsidolimab in generalized pustular psoriasis (GPP)" https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-088239): "FDA accepted the BLA filing for imsidolimab in generalized pustular psoriasis (GPP) in Feb. 2026 with a target action date of Dec. 12, 2026" https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-219515): "The FDA accepted the BLA filing for imsidolimab in GPP in February 2026 with a target action date of December 12, 2026." https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm
- SEC Form 10-K (accession 0001193125-26-088290): "The FDA accepted the BLA filing for imsidolimab in GPP in February 2026 with a target action date of December 12, 2026." https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/anab-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-458461): "FDA target action date (PDUFA) of December 12, 2026, for Quimilza in generalized pustular psoriasis (GPP)" https://www.sec.gov/Archives/edgar/data/1370053/000119312526458461/anab-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-458494): "The FDA accepted the BLA filing for Quimilza in GPP in February 2026 with a target action date of December 12, 2026." https://www.sec.gov/Archives/edgar/data/1370053/000119312526458494/anab-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-067886): "•The Biologics License Application (BLA) for Quimilza™ in Generalized Pustular Psoriasis (GPP) is under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026." https://www.sec.gov/Archives/edgar/data/1347178/000162828026067886/vnda8-k10282026exhibit991.htm
- SEC Form 10-Q (accession 0001347178-26-000002): "•The Biologics License Application (BLA) for Quimilza™ in Generalized Pustular Psoriasis (GPP) is under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026." https://www.sec.gov/Archives/edgar/data/1347178/000134717826000002/vnda-20260930.htm

Calendar months: [February 2026](https://sec-api.dev/fda-calendar/2026-02), [December 2026](https://sec-api.dev/fda-calendar/2026-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/imsidolimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Imsidolimab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/imsidolimab

```bibtex
@misc{secapidev_pdufa_imsidolimab_20261116,
  title        = {Imsidolimab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/imsidolimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_imsidolimab_20261116","title":"Imsidolimab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/imsidolimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
